...up front and is eligible for $27 million in milestones, plus single-digit royalties. Marina (formerly MDRNA Inc.... ...interfering RNA-based therapeutics, said the intranasal formulation of carbetocin was developed by its predecessor company, Nastech...
MDRNA Inc. implemented a 1-for-4 reverse stock split, changed its name to Marina Biotech Inc. and began trading under the symbol "MRNAD." Following the split, the company will have 12.2 million shares outstanding. Marina Biotech...
...technology to a 2009 deal granting MDRNA rights to use the technology for human therapeutics. MDRNA... ...technology for use in reagents. Financial terms were not disclosed (see BioCentury, June 29, 2009). MDRNA Inc....
...up front and is eligible for $27 million in milestones, plus single-digit royalties. Marina (formerly MDRNA Inc.... ...interfering RNA-based therapeutics, said the intranasal formulation of carbetocin was developed by its predecessor company, Nastech...
MDRNA Inc. implemented a 1-for-4 reverse stock split, changed its name to Marina Biotech Inc. and began trading under the symbol "MRNAD." Following the split, the company will have 12.2 million shares outstanding. Marina Biotech...
...technology to a 2009 deal granting MDRNA rights to use the technology for human therapeutics. MDRNA... ...technology for use in reagents. Financial terms were not disclosed (see BioCentury, June 29, 2009). MDRNA Inc....
